Want to see AU:CGS full AI Analyst Report?
CGS Stock Chart & Stats
AU$2.53
-AU$0.05(-1.98%)
At close: 4:00 PM EDT
AU$2.53
-AU$0.05(-1.98%)
Day’s Range― - ―
52-Week RangeAU$1.55 - AU$3.01
Previous CloseN/A
Volume167.93K
Average Volume (3M)355.93K
Market Cap
AU$424.80M
Enterprise ValueAU$349.87
Total Cash (Recent Filing)AU$34.07M
Total Debt (Recent Filing)AU$716.74K
Price to Earnings (P/E)27.2
Beta0.15
Next Earnings
Aug 18, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)0.06
Shares Outstanding169,919,360
10 Day Avg. Volume327,690
30 Day Avg. Volume355,934
Financial Highlights & Ratios
PEG Ratio1.95
Price to Book (P/B)6.26
Price to Sales (P/S)9.00
P/FCF Ratio35.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.43Price Target Upside35.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.08
Revenue Forecast (FY)AU$67.65M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And LiquidityCogstate's cash cushion ($34.1M) and essentially no debt (debt-to-equity ~0.01; equity ratio ~73.9%) provide durable financial optionality. This capital flexibility supports cycle resilience against trial-timing volatility, funds targeted tech investment and delivery expansion, and underpins dividend and buyback optionality.
Visible Contracted Backlog And Forward RevenueA $92.3M backlog and materially higher contracted revenue for upcoming periods give durable revenue visibility. This forward book reduces short-term execution risk, supports margin recovery as fixed costs leverage, and underpins multi-period planning for delivery capacity and product investment.
High Margins And Operational LeverageSustained high gross and EBITDA margins demonstrate strong unit economics in cognitive assessment services. Combined with record trial starts and channel partner-driven sales, margins create long-term profitability leverage as scale grows, allowing continued R&D/AI investment without structurally diluting returns.
Bears Say
Sharp Recent Revenue DeclineA 34.2% revenue drop materially reduces operational scale and raises execution risk: fixed delivery costs become harder to absorb, cadence of study starts drives near-term revenue volatility, and management must translate backlog into booked revenue to re‑establish growth momentum.
Weakened Free Cash Flow GenerationA >50% decline in free cash flow constrains internal funding for technology, delivery expansion, or M&A and increases reliance on cash reserves. If persistent, lower FCF pressures dividend policy flexibility and reduces buffer for trial timing mismatches or one-off provisions.
Concentration And Revenue Timing VolatilityDependence on large Alzheimer’s presymptomatic programs creates boom‑and‑bust revenue cycles; license-fee mix shifts and delayed recognition (Phase IV/RWE deals) amplify quarter-to-half timing swings. This structural volatility complicates forecasting and can depress realized margin conversion despite healthy backlog.
Cogstate Ltd News
CGS FAQ
What was Cogstate Ltd’s price range in the past 12 months?
Cogstate Ltd lowest share price was AU$1.55 and its highest was AU$3.01 in the past 12 months.
What is Cogstate Ltd’s market cap?
Cogstate Ltd’s market cap is AU$424.80M.
When is Cogstate Ltd’s upcoming earnings report date?
Cogstate Ltd’s upcoming earnings report date is Aug 18, 2026 which is in 15 days.
How were Cogstate Ltd’s earnings last quarter?
Cogstate Ltd released its earnings results on Feb 18, 2026. The company reported AU$0.037 earnings per share for the quarter, beating the consensus estimate of AU$0.03 by AU$0.007.
Is Cogstate Ltd overvalued?
According to Wall Street analysts Cogstate Ltd’s price is currently Undervalued.
Does Cogstate Ltd pay dividends?
Cogstate Ltd pays a Notavailable dividend of AU$0.02 which represents an annual dividend yield of 0.8%. See more information on Cogstate Ltd dividends here
What is Cogstate Ltd’s EPS estimate?
Cogstate Ltd’s EPS estimate is 0.05.
How many shares outstanding does Cogstate Ltd have?
Cogstate Ltd has 169,919,360 shares outstanding.
What happened to Cogstate Ltd’s price movement after its last earnings report?
Cogstate Ltd reported an EPS of AU$0.037 in its last earnings report, beating expectations of AU$0.03. Following the earnings report the stock price went up 8.716%.
Which hedge fund is a major shareholder of Cogstate Ltd?
Currently, no hedge funds are holding shares in AU:CGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogstate Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.43 (35.38% Upside)
AU$3.43 (35.38% Upside)
Blogger Sentiment
Bullish
AU:CGS Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth AU$10.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
140.24%
12-Months-Change
Fundamentals
Return on Equity
0.80%
Trailing 12-Months
Asset Growth
12.30%
Trailing 12-Months
Company Description
Cogstate Ltd
Cogstate Ltd (CGS) is a healthcare technology company focused on neuroscience and brain health assessment. The company develops and provides computerized cognitive tests and related digital assessment tools used primarily in clinical trials and research to measure cognitive function and detect cognitive change, supporting programs in areas such as Alzheimer’s disease and other central nervous system (CNS) conditions. Cogstate’s offerings are used by biopharmaceutical sponsors, clinical research organizations, and academic/medical researchers as part of study endpoints and participant monitoring.
CGS Stock 12 Month Forecast
Average Price Target
AU$3.43
▲(35.38% Upside)
Technical Analysis
Tali Digital
―
Opyl Ltd.
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
PainChek Ltd
―





